ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 08, 2021
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for April 23, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … April 05, 2021
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Press release Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally October 05, 2020
ProQR Announces Virtual Presentations at Scientific Conferences Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. September 24, 2020
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … July 14, 2020
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO Press release … amaurosis 10, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA … October 07, 2019
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … April 13, 2021
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … March 31, 2021
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release … such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA … March 30, 2021
